These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31436911)

  • 1. Discovery of potential Toxoplasma gondii CDPK1 inhibitors with new scaffolds based on the combination of QSAR and scaffold-hopping method with in vitro validation.
    Zhang P; Jia L; Tian Y; Xi L; Duan R; Chen X; Xiao J; Yao X; Lan J; Li S
    Chem Biol Drug Des; 2020 May; 95(5):476-484. PubMed ID: 31436911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.
    Johnson SM; Murphy RC; Geiger JA; DeRocher AE; Zhang Z; Ojo KK; Larson ET; Perera BG; Dale EJ; He P; Reid MC; Fox AM; Mueller NR; Merritt EA; Fan E; Parsons M; Van Voorhis WC; Maly DJ
    J Med Chem; 2012 Mar; 55(5):2416-26. PubMed ID: 22320388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
    Rutaganira FU; Barks J; Dhason MS; Wang Q; Lopez MS; Long S; Radke JB; Jones NG; Maddirala AR; Janetka JW; El Bakkouri M; Hui R; Shokat KM; Sibley LD
    J Med Chem; 2017 Dec; 60(24):9976-9989. PubMed ID: 28933846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
    Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
    J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step.
    Sugi T; Kato K; Kobayashi K; Watanabe S; Kurokawa H; Gong H; Pandey K; Takemae H; Akashi H
    Eukaryot Cell; 2010 Apr; 9(4):667-70. PubMed ID: 20173034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
    Zhang Z; Ojo KK; Johnson SM; Larson ET; He P; Geiger JA; Castellanos-Gonzalez A; White AC; Parsons M; Merritt EA; Maly DJ; Verlinde CL; Van Voorhis WC; Fan E
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5264-7. PubMed ID: 22795629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.
    Scheele S; Geiger JA; DeRocher AE; Choi R; Smith TR; Hulverson MA; Vidadala RSR; Barrett LK; Maly DJ; Merritt EA; Ojo KK; Van Voorhis WC; Parsons M
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
    Moine E; Dimier-Poisson I; Enguehard-Gueiffier C; Logé C; Pénichon M; Moiré N; Delehouzé C; Foll-Josselin B; Ruchaud S; Bach S; Gueiffier A; Debierre-Grockiego F; Denevault-Sabourin C
    Eur J Med Chem; 2015 Nov; 105():80-105. PubMed ID: 26479029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.
    Ojo KK; Larson ET; Keyloun KR; Castaneda LJ; Derocher AE; Inampudi KK; Kim JE; Arakaki TL; Murphy RC; Zhang L; Napuli AJ; Maly DJ; Verlinde CL; Buckner FS; Parsons M; Hol WG; Merritt EA; Van Voorhis WC
    Nat Struct Mol Biol; 2010 May; 17(5):602-7. PubMed ID: 20436472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Molecules To Treat Chronic Central Nervous System Toxoplasmosis.
    Kortagere S
    J Med Chem; 2017 Dec; 60(24):9974-9975. PubMed ID: 29200288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.
    Cardew EM; Verlinde CLMJ; Pohl E
    Parasitology; 2018 Feb; 145(2):210-218. PubMed ID: 29191253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Potential Kinase Inhibitors within the PI3K/AKT Pathway of
    Ochoa R; Ortega-Pajares A; Castello FA; Serral F; Fernández Do Porto D; Villa-Pulgarin JA; Varela-M RE; Muskus C
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
    Larson ET; Ojo KK; Murphy RC; Johnson SM; Zhang Z; Kim JE; Leibly DJ; Fox AM; Reid MC; Dale EJ; Perera BG; Kim J; Hewitt SN; Hol WG; Verlinde CL; Fan E; Van Voorhis WC; Maly DJ; Merritt EA
    J Med Chem; 2012 Mar; 55(6):2803-10. PubMed ID: 22369268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based quantitative structure-activity relationship studies of checkpoint kinase 1 inhibitors.
    Du J; Xi L; Lei B; Lu J; Li J; Liu H; Yao X
    J Comput Chem; 2010 Nov; 31(15):2783-93. PubMed ID: 20839304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the Target of an Antiparasitic Compound in
    Herneisen AL; Sidik SM; Markus BM; Drewry DH; Zuercher WJ; Lourido S
    ACS Chem Biol; 2020 Jul; 15(7):1801-1807. PubMed ID: 32597628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
    Li R; Du Y; Shen J
    SAR QSAR Environ Res; 2018 Nov; 29(11):847-873. PubMed ID: 30280589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.